Oxurion (Euronext Brussels: OXUR - formerly known as ThromboGenics) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye. The company has built a diverse portfolio of disease-modifying therapies, including treatments for diabetic eye disease, a leading cause of blindness in people of working age worldwide.

Biotechnology

Oxurion

Grace Chang

Andy De Deene

Kathleen Paisley

Linda Knott

An Huysmans

Philippe B.

Alfred Aronson

Leadership Team

Corporate Governance

Medical and Scientific Team

Teams at Oxurion

Leadership Team

Corporate Governance

Medical and Scientific Team